Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NYSE:ZBH
- CUSIP: N/A
- Web: www.zimmerbiomet.com
Capitalization:- Market Cap: $22.84207 billion
- Outstanding Shares: 202,195,000
Average Prices:- 50 Day Moving Avg: $123.56
- 200 Day Moving Avg: $121.24
- 52 Week Range: $95.63 - $133.49
P/E:- Trailing P/E Ratio: 32.21
- Foreward P/E Ratio: 12.76
- P/E Growth: 1.62
Sales & Book Value:- Annual Revenue: $7.78 billion
- Price / Sales: 2.94
- Book Value: $50.86 per share
- Price / Book: 2.22
Dividend:- Annual Dividend: $0.96
- Dividend Yield: 0.9%
Profitability:- EBIDTA: $2.8 billion
- Net Margins: 9.12%
- Return on Equity: 16.70%
- Return on Assets: 6.18%
Debt:- Debt-to-Equity Ratio: 0.91%
- Current Ratio: 1.48%
- Quick Ratio: 0.80%
Misc:- Average Volume: 1.46 million shs.
- Beta: 1.2
- Short Ratio: 3.17
Frequently Asked Questions for Zimmer Biomet Holdings (NYSE:ZBH)
What is Zimmer Biomet Holdings' stock symbol?
Zimmer Biomet Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet Holdings pay dividends? What is the dividend yield for Zimmer Biomet Holdings?
Zimmer Biomet Holdings announced a quarterly dividend on Monday, August 7th. Stockholders of record on Friday, September 22nd will be given a dividend of $0.24 per share on Friday, October 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Thursday, September 21st. View Zimmer Biomet Holdings' Dividend History.
How were Zimmer Biomet Holdings' earnings last quarter?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its quarterly earnings data on Thursday, July, 27th. The company reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by $0.02. The company earned $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. Zimmer Biomet Holdings's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.02 EPS. View Zimmer Biomet Holdings' Earnings History.
When will Zimmer Biomet Holdings make its next earnings announcement?
What guidance has Zimmer Biomet Holdings issued on next quarter's earnings?
Zimmer Biomet Holdings issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $8.20-8.30 for the period, compared to the Thomson Reuters consensus estimate of $8.51. The company issued revenue guidance of $7.8-7.87 billion, compared to the consensus revenue estimate of $7.86 billion.Zimmer Biomet Holdings also updated its Q3 guidance to $1.72-1.77 EPS.
Where is Zimmer Biomet Holdings' stock going? Where will Zimmer Biomet Holdings' stock price be in 2017?
21 analysts have issued 12-month price objectives for Zimmer Biomet Holdings' stock. Their forecasts range from $92.00 to $158.00. On average, they anticipate Zimmer Biomet Holdings' share price to reach $138.84 in the next year. View Analyst Ratings for Zimmer Biomet Holdings.
What are analysts saying about Zimmer Biomet Holdings stock?
Here are some recent quotes from research analysts about Zimmer Biomet Holdings stock:
- 1. According to Zacks Investment Research, "Zimmer Biomet ended the second quarter on a mixed note. While earnings topped the Zacks Consensus Estimate, revenues remained in line with the same. We are disappointed by the company's declining sales performance within several of its core segments. Moreover, the market seems to be apprehensive about the departure of Zimmer’s decade old CEO David C. Dvorak. Zimmer Biomet has been lagging the broader industry with respect to share price movement over the last three months. The trimmed 2017 guidance adds to our concerns indicating little chances of recovery ahead. Nevertheless, improved gross and operating margin performance was encouraging. We look forward to the expected synergy from the LDR Holding acquisition, which should broaden and complement the company's musculoskeletal offering. We are also impressed by the strong strategic and financial goals which the combined entity expects to reach, now that the deal has been closed." (8/8/2017)
- 2. Canaccord Genuity analysts commented, "SGEN reported 1Q earnings and provided a pipeline update." (4/28/2017)
- 3. Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
Who are some of Zimmer Biomet Holdings' key competitors?
Some companies that are related to Zimmer Biomet Holdings include Baxter International (BAX), C.R. Bard (BCR), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), Steris Plc (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), NuVasive (NUVA), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE) and Halyard Health (HYH).
Who are Zimmer Biomet Holdings' key executives?
Zimmer Biomet Holdings' management team includes the folowing people:
- Daniel P. Florin, Interim Chief Executive Officer, Chief Financial Officer, Director
- Robert D. Delps, President, Americas
- Katarzyna Mazur-Hofsaess M.D. Ph.D., President, Europe, Middle East and Africa
- Sang Yi, President, Asia Pacific
- Chad F. Phipps, Senior Vice President, General Counsel, Secretary
- Larry C. Glasscock, Independent Non-Executive Chairman of the Board
- Christopher B. Begley, Independent Director
- Betsy J. Bernard, Independent Director
- Gail Koziara Boudreaux, Independent Director
- Michael Farrell, Independent Director
Who owns Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.63%), Vanguard Group Inc. (6.63%), State Street Corp (4.06%), Longview Partners Guernsey LTD (3.16%), Nordea Investment Management AB (2.44%) and Northern Trust Corp (1.99%). Company insiders that own Zimmer Biomet Holdings stock include Blackstone Capital Partners V, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet Holdings.
Who sold Zimmer Biomet Holdings stock? Who is selling Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., FMR LLC, Alliancebernstein L.P., Ameriprise Financial Inc., California Public Employees Retirement System, Marshall Wace North America L.P., Focused Investors LLC and Tudor Investment Corp ET AL. Company insiders that have sold Zimmer Biomet Holdings stock in the last year include Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet Holdings.
Who bought Zimmer Biomet Holdings stock? Who is buying Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Harbour Capital Advisors LLC, Koch Industries Inc., BlackRock Inc., Northern Trust Corp, Thrivent Financial For Lutherans, HealthCor Management L.P. and Vanguard Group Inc.. View Insider Buying and Selling for Zimmer Biomet Holdings.
How do I buy Zimmer Biomet Holdings stock?
Shares of Zimmer Biomet Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zimmer Biomet Holdings' stock price today?
One share of Zimmer Biomet Holdings stock can currently be purchased for approximately $113.08.
MarketBeat Community Rating for Zimmer Biomet Holdings (NYSE ZBH)MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zimmer Biomet Holdings (NYSE:ZBH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $138.84 (22.78% upside) |
Analysts' Ratings History for Zimmer Biomet Holdings (NYSE:ZBH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/14/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $137.00 | Low |  |
| 7/28/2017 | BMO Capital Markets | Boost Price Target | Outperform | $136.00 -> $140.00 | Low | |
| 7/28/2017 | Leerink Swann | Boost Price Target | Outperform | $141.00 -> $146.00 | Low | |
| 7/28/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $135.00 | Medium | |
| 7/28/2017 | Canaccord Genuity | Downgrade | Buy -> Hold | $141.00 -> $135.00 | Medium | |
| 7/27/2017 | Cantor Fitzgerald | Set Price Target | Hold | $137.00 | Low | |
| 7/17/2017 | Morgan Stanley | Boost Price Target | Overweight | $137.00 -> $150.00 | Low | |
| 7/14/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $125.00 | Low | |
| 7/14/2017 | Bank of America Corporation | Reiterated Rating | Buy -> Buy | $158.00 | Medium | |
| 7/14/2017 | Wells Fargo & Company | Reiterated Rating | Market Weight | | High | |
| 7/14/2017 | Royal Bank Of Canada | Reiterated Rating | Outperform | $140.00 | High | |
| 7/12/2017 | Needham & Company LLC | Reiterated Rating | Strong-Buy | $153.00 | Low | |
| 7/12/2017 | Guggenheim | Upgrade | Neutral -> Buy | $157.00 | Medium | |
| 6/30/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $148.00 | Low | |
| 6/9/2017 | Citigroup Inc. | Boost Price Target | Neutral | $108.00 -> $130.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Sell -> Sell | $92.00 | High | |
| 2/1/2017 | Robert W. Baird | Reiterated Rating | Outperform | $130.00 -> $136.00 | N/A | |
| 1/5/2017 | J P Morgan Chase & Co | Set Price Target | Buy | $134.00 | N/A | |
| 11/8/2016 | Northcoast Research | Downgrade | Buy -> Neutral | | N/A | |
| 9/22/2016 | Argus | Reiterated Rating | Buy | $140.00 | N/A | |
| 8/23/2016 | Barclays PLC | Boost Price Target | Overweight | $140.00 -> $145.00 | N/A | |
| 8/11/2016 | SunTrust Banks, Inc. | Initiated Coverage | Buy | $155.00 | N/A | |
| 7/29/2016 | JMP Securities | Boost Price Target | Market Outperform | $131.00 -> $145.00 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Buy | | N/A | |
| 3/17/2016 | Nomura | Initiated Coverage | Buy | $123.00 | N/A | |
| 1/31/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 1/29/2016 | Northland Securities | Lower Price Target | | $109.00 -> $105.00 | N/A | |
| 10/30/2015 | Brean Capital | Reiterated Rating | Hold | | N/A | |
| 10/9/2015 | Credit Suisse Group | Initiated Coverage | Outperform | $107.00 | N/A | |
(Data available from 8/17/2015 forward)
Earnings History for Zimmer Biomet Holdings (NYSE:ZBH)Earnings History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | $1.83 | | | | | N/A | |
| 7/27/2017 | Q2 2017 | $2.10 | $2.08 | $1.95 billion | $1.95 billion | View | N/A | |
| 4/27/2017 | Q1 2017 | $2.11 | $2.13 | $1.96 billion | $1.98 billion | View | N/A | |
| 1/31/2017 | Q416 | $2.11 | $2.14 | $1.98 billion | $2.01 billion | View | Listen | |
| 10/31/2016 | Q316 | $1.79 | $1.79 | $950.20 million | $1.83 billion | View | Listen | |
| 7/28/2016 | Q216 | $1.97 | $2.02 | $1.90 billion | $1.93 billion | View | Listen | |
| 4/28/2016 | Q116 | $1.93 | $2.00 | $1.88 billion | $1.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $2.04 | $2.09 | $1.96 billion | $1.98 billion | View | Listen | |
| 10/29/2015 | Q315 | $1.56 | $1.64 | $1.76 billion | $1.76 billion | View | Listen | |
| 4/30/2015 | Q115 | $1.54 | $1.58 | $1.15 billion | $1.13 billion | View | N/A | |
| 1/29/2015 | Q414 | $1.71 | $0.91 | $1.25 billion | $1.22 billion | View | N/A | |
| 10/23/2014 | Q314 | $1.00 | $0.96 | $1.10 billion | $1.11 billion | View | Listen | |
| 7/24/2014 | Q214 | $1.49 | $1.49 | $1.21 billion | $1.18 billion | View | N/A | |
| 4/24/2014 | Q114 | $1.47 | $1.50 | $1.18 billion | $1.16 billion | View | Listen | |
| 1/31/2014 | Q114 | $1.62 | $1.36 | $1.22 billion | $1.24 billion | View | N/A | |
| 10/24/2013 | Q313 | $1.24 | $1.25 | $1.06 billion | $1.07 billion | View | N/A | |
| 7/25/2013 | Q2 2013 | $1.44 | $1.43 | $1.15 billion | $1.17 billion | View | N/A | |
| 4/25/2013 | Q1 2013 | $1.40 | $1.41 | $1.14 billion | $1.14 billion | View | N/A | |
| 1/31/2013 | Q4 2012 | $1.49 | $1.51 | $1.17 billion | $1.18 billion | View | N/A | |
| 10/25/2012 | | $1.13 | $1.15 | | | View | N/A | |
| 7/26/2012 | | $1.32 | $1.34 | | | View | N/A | |
| 4/26/2012 | | $1.30 | $1.30 | | | View | N/A | |
| 1/26/2012 | | $1.34 | $1.36 | | | View | N/A | |
| 10/27/2011 | | $1.03 | $1.04 | | | View | N/A | |
| 7/27/2011 | | $1.19 | $1.21 | | | View | N/A | |
| 4/28/2011 | | $1.12 | $1.19 | | | View | N/A | |
| 1/27/2011 | | $1.19 | $1.21 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zimmer Biomet Holdings (NYSE:ZBH)2017 EPS Consensus Estimate: $8.32
2018 EPS Consensus Estimate: $9.18
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | $2.10 | $2.14 | $2.11 |
| Q2 2017 | 6 | $2.08 | $2.18 | $2.12 |
| Q3 2017 | 6 | $1.73 | $1.93 | $1.79 |
| Q4 2017 | 6 | $2.26 | $2.41 | $2.30 |
| Q1 2018 | 3 | $2.22 | $2.32 | $2.28 |
| Q2 2018 | 3 | $2.17 | $2.39 | $2.27 |
| Q3 2018 | 2 | $1.97 | $2.18 | $2.08 |
| Q4 2018 | 2 | $2.51 | $2.59 | $2.55 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Zimmer Biomet Holdings (NYSE:ZBH)| Next Dividend: | 10/27/2017 |
| Annual Dividend: | $0.96 |
| Dividend Yield: | 0.85% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio: | 27.59% (Trailing 12 Months of Earnings)
11.65% (Based on This Year's Estimates)
10.84% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Zimmer Biomet Holdings (NYSE ZBH)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/7/2017 | quarterly | $0.24 | 0.83% | 9/21/2017 | 9/22/2017 | 10/27/2017 |
| 5/30/2017 | quarterly | $0.24 | 0.81% | 6/21/2017 | 6/23/2017 | 7/28/2017 |
| 3/1/2017 | quarterly | $0.24 | 0.81% | 3/29/2017 | 3/31/2017 | 4/28/2017 |
| 12/19/2016 | quarterly | $0.24 | 0.94% | 12/28/2016 | 12/30/2016 | 1/27/2017 |
| 8/23/2016 | quarterly | $0.24 | 0.74% | 9/21/2016 | 9/23/2016 | 10/28/2016 |
| 5/23/2016 | quarterly | $0.24 | | 6/22/2016 | 6/24/2016 | 7/29/2016 |
| 2/24/2016 | quarterly | $0.24 | 0.99% | 3/29/2016 | 3/31/2016 | 4/29/2016 |
| 12/14/2015 | quarterly | $0.22 | 0.87% | 12/29/2015 | 12/31/2015 | 1/29/2016 |
| 8/24/2015 | quarterly | $0.22 | 0.9% | 9/28/2015 | 9/30/2015 | 10/30/2015 |
| 5/5/2015 | quarterly | $0.22 | 0.8% | 5/13/2015 | 5/15/2015 | 7/14/2015 |
| 2/24/2015 | quarterly | $0.22 | 0.73% | 3/4/2015 | 3/6/2015 | 4/24/2015 |
| 12/15/2014 | quarterly | $0.22 | 0.81% | 12/24/2014 | 12/29/2014 | 1/30/2015 |
| 8/26/2014 | quarterly | $0.22 | 0.87% | 9/24/2014 | 9/26/2014 | 10/31/2014 |
| 5/23/2014 | quarterly | $0.22 | 0.86% | 6/25/2014 | 6/27/2014 | 7/25/2014 |
| 3/5/2014 | quarterly | $0.22 | 0.9% | 3/26/2014 | 3/28/2014 | 4/25/2014 |
| 12/16/2013 | quarterly | $0.20 | 0.88% | 12/24/2013 | 12/27/2013 | 1/31/2014 |
| 9/9/2013 | quarterly | $0.20 | 0.99% | 9/25/2013 | 9/27/2013 | 10/25/2013 |
| 6/14/2013 | quarterly | $0.20 | 1.03% | 6/26/2013 | 6/28/2013 | 7/26/2013 |
| 3/8/2013 | quarterly | $0.20 | 1.06% | 3/26/2013 | 3/29/2013 | 4/26/2013 |
| 12/14/2012 | quarterly | $0.18 | 1.06% | 12/24/2012 | 12/27/2012 | 1/25/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Zimmer Biomet Holdings (NYSE:ZBH)Insider Ownership Percentage: 1.07%
Institutional Ownership Percentage: 82.84%
Insider Trades by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/31/2017 | Tony W. Collins | VP | Sell | 16,986 | $121.74 | $2,067,875.64 | |
| 6/12/2017 | Sang Yi | Insider | Sell | 17,731 | $124.56 | $2,208,573.36 | |
| 5/5/2017 | Chad F. Phipps | VP | Sell | 6,200 | $116.76 | $723,912.00 | |
| 4/27/2017 | David C Dvorak | Insider | Sell | 87,331 | $116.47 | $10,171,441.57 | |
| 3/20/2017 | David C Dvorak | Insider | Sell | 1,040 | $121.63 | $126,495.20 | |
| 12/2/2016 | David A. Jr. Nolan | Insider | Sell | 5,050 | $101.11 | $510,605.50 | |
| 9/8/2016 | Daniel E Williamson | Insider | Sell | 2,716 | $129.96 | $352,971.36 | |
| 8/23/2016 | Stuart G Kleopfer | Insider | Sell | 3,397 | $129.71 | $440,624.87 | |
| 8/12/2016 | Tony W. Collins | VP | Sell | 1,287 | $129.16 | $166,228.92 | |
| 8/9/2016 | Stuart G Kleopfer | Insider | Sell | 533 | $132.71 | $70,734.43 | |
| 8/1/2016 | David A. Jr. Nolan | Insider | Sell | 25,255 | $130.77 | $3,302,596.35 | |
| 7/11/2016 | Daniel P Florin | CFO | Sell | 15,000 | $124.98 | $1,874,700.00 | |
| 6/14/2016 | Tony W Collins | CAO | Sell | 3,611 | $116.43 | $420,428.73 | |
| 6/9/2016 | Stuart G Kleopfer | Insider | Sell | 11,000 | $119.45 | $1,313,950.00 | |
| 4/14/2016 | Daniel P Florin | CFO | Sell | 10,000 | $114.98 | $1,149,800.00 | |
| 4/12/2016 | Daniel P Florin | CFO | Sell | 12,000 | $110.00 | $1,320,000.00 | |
| 3/21/2016 | David C Dvorak | CEO | Sell | 1,540 | $104.16 | $160,406.40 | |
| 2/10/2016 | Blackstone Capital Partners V | Major Shareholder | Sell | 7,351,708 | $95.91 | $705,102,314.28 | |
| 1/8/2016 | David C. Dvorak | CEO | Sell | 44,661 | $102.46 | $4,575,966.06 | |
| 12/2/2015 | David A. Jr. Nolan | insider | Sell | 3,435 | $102.62 | $352,499.70 | |
| 6/30/2015 | Adam Rudolph Johnson | Insider | Sell | 30,600 | $110.34 | $3,376,404.00 | |
| 6/29/2015 | Daniel E Williamson | Insider | Sell | 16,000 | $110.98 | $1,775,680.00 | |
| 6/29/2015 | Daniel P Florin | CFO | Sell | 5,000 | $107.00 | $535,000.00 | |
| 3/17/2015 | David C Dvorak | CEO | Sell | 1,300 | $115.55 | $150,215.00 | |
| 12/5/2014 | David C Dvorak | CEO | Sell | 48,703 | $115.00 | $5,600,845.00 | |
| 11/28/2014 | Chad F Phipps | VP | Sell | 5,000 | $112.00 | $560,000.00 | |
| 11/3/2014 | Katarzyna Mazur-Hofsaess | Insider | Sell | 28,253 | $110.01 | $3,108,112.53 | |
| 9/9/2014 | Stephen Hong Liang Ooi | Insider | Sell | 40,768 | $102.78 | $4,190,135.04 | |
| 8/26/2014 | James T Crines | CFO | Sell | 40,768 | $101.00 | $4,117,568.00 | |
| 1/8/2014 | Jeffery Mccaulley | Insider | Sell | 21,286 | $96.00 | $2,043,456.00 | |
| 1/7/2014 | Chad Phipps | VP | Sell | 7,000 | $95.00 | $665,000.00 | |
| 12/20/2013 | Jeffery Mccaulley | Insider | Sell | 21,286 | $93.00 | $1,979,598.00 | |
| 12/3/2013 | Jeffery Mccaulley | Insider | Sell | 2,713 | $90.12 | $244,495.56 | |
| 11/15/2013 | Derek Davis | CAO | Sell | 3,500 | $90.20 | $315,700.00 | |
| 11/14/2013 | Chad Phipps | VP | Sell | 7,800 | $90.00 | $702,000.00 | |
| 11/14/2013 | David Dvorak | CEO | Sell | 64,763 | $90.00 | $5,828,670.00 | |
| 11/14/2013 | Jeffery Mccaulley | Insider | Sell | 21,285 | $90.00 | $1,915,650.00 | |
| 9/13/2013 | Katarzyna Mazur-Hofsaess | Insider | Sell | 4,890 | $81.38 | $397,948.20 | |
| 8/1/2013 | James T Crines | CFO | Sell | 46,200 | $84.56 | $3,906,672.00 | |
| 8/1/2013 | Stephen Hong Liang Ooi | Insider | Sell | 38,500 | $84.27 | $3,244,395.00 | |
| 7/29/2013 | Derek M Davis | CAO | Sell | 3,725 | $83.78 | $312,080.50 | |
| 7/29/2013 | Jeffery A Mccaulley | Insider | Sell | 112,255 | $83.40 | $9,362,067.00 | |
| 7/19/2013 | Chad F Phipps | VP | Sell | 6,000 | $83.00 | $498,000.00 | |
| 5/8/2013 | Chad F Phipps | VP | Sell | 5,000 | $77.26 | $386,300.00 | |
| 4/30/2013 | James T Crines | CFO | Sell | 25,000 | $76.08 | $1,902,000.00 | |
| 4/30/2013 | Jeffery A Mccaulley | Insider | Sell | 10,000 | $76.08 | $760,800.00 | |
| 2/4/2013 | Derek M Davis | CAO | Sell | 21,864 | $72.53 | $1,585,795.92 | |
| 2/4/2013 | Jeffery A Mccaulley | Insider | Sell | 12,000 | $73.60 | $883,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zimmer Biomet Holdings (NYSE:ZBH)
Latest Headlines for Zimmer Biomet Holdings (NYSE:ZBH)
| Source: |
|
| Date | Headline |
|---|
 | Reviewing Zimmer Biomet Holdings (NYSE:ZBH) and CryoLife (CRY)
www.americanbankingnews.com - August 14 at 8:06 PM |
 | New Strong Sell Stocks for August 14th
finance.yahoo.com - August 14 at 8:38 AM |
| Zimmer Biomet Holdings, Inc. – Value Analysis (NYSE:ZBH) : August 12, 2017
finance.yahoo.com - August 12 at 9:04 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Downgraded by Zacks Investment Research to Strong Sell
www.americanbankingnews.com - August 8 at 2:36 PM |
| Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2017
finance.yahoo.com - August 8 at 8:33 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 8 at 7:46 AM |
| Zimmer Biomet Holdings, Inc. Plans Quarterly Dividend of $0.24 (ZBH)
www.americanbankingnews.com - August 7 at 6:34 PM |
 | Two Stocks To Buy And Forget For The Next Decade--Stryker And Zimmer - Forbes
www.forbes.com - August 7 at 8:52 AM |
| SunTrust Banks Research Analysts Cut Earnings Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
www.americanbankingnews.com - August 7 at 7:04 AM |
| $1.84 Billion in Sales Expected for Zimmer Biomet Holdings, Inc. (ZBH) This Quarter
www.americanbankingnews.com - August 5 at 9:08 AM |
 | Zimmer Biomet Holdings Breaks Below 200-Day Moving Average - Notable for ZBH - Nasdaq
www.nasdaq.com - August 4 at 10:19 AM |
| Limacorporate S.p.A. -- Moody's assigns Ba2 rating to Lima's RCF
finance.yahoo.com - August 3 at 9:14 AM |
| Zacks: Analysts Expect Zimmer Biomet Holdings, Inc. (ZBH) to Post $1.75 EPS
www.americanbankingnews.com - August 3 at 7:52 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) VP Tony W. Collins Sells 16,986 Shares
www.americanbankingnews.com - August 2 at 7:26 PM |
| Q4 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Decreased by Analyst
www.americanbankingnews.com - August 2 at 1:14 PM |
| FY2017 EPS Estimates for Zimmer Biomet Holdings, Inc. Decreased by Analyst (ZBH)
www.americanbankingnews.com - August 2 at 9:44 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 1 at 12:56 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Downgraded by BidaskClub
www.americanbankingnews.com - August 1 at 8:05 AM |
| Moody's assigns B2 to Lima, stable outlook
finance.yahoo.com - August 1 at 8:04 AM |
| Northcoast Research Comments on Zimmer Biomet Holdings, Inc.'s Q3 2017 Earnings (NYSE:ZBH)
www.americanbankingnews.com - August 1 at 7:23 AM |
| Zimmer Biomet Holdings, Inc. Expected to Earn Q3 2017 Earnings of $1.76 Per Share (NYSE:ZBH)
www.americanbankingnews.com - July 31 at 7:03 AM |
| Q3 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (ZBH) Decreased by Oppenheimer Holdings
www.americanbankingnews.com - July 31 at 7:03 AM |
| Q3 2017 EPS Estimates for Zimmer Biomet Holdings, Inc. (ZBH) Decreased by Analyst
www.americanbankingnews.com - July 31 at 7:03 AM |
| Canaccord Genuity Lowers Zimmer Biomet Holdings, Inc. (ZBH) to Hold
www.americanbankingnews.com - July 30 at 5:16 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - July 30 at 2:39 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT Set at $137.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 30 at 1:31 PM |
| Edited Transcript of ZBH earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 29 at 1:34 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Given New $140.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - July 28 at 9:08 PM |
| Leerink Swann Increases Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target to $146.00
www.americanbankingnews.com - July 28 at 9:08 PM |
| Zimmer Biomet (ZBH) Misses Q2 Earnings, Meets Sales Estimate - Nasdaq
www.nasdaq.com - July 28 at 10:21 AM |
| Zimmer misses 2Q profit forecasts
finance.yahoo.com - July 28 at 10:21 AM |
| Zimmer Biomet Holdings, Inc. breached its 50 day moving average in a Bearish Manner : ZBH-US : July 28, 2017
finance.yahoo.com - July 28 at 10:21 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given a $137.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - July 27 at 6:43 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - July 27 at 4:59 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Releases FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 9:59 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Issues Q3 Earnings Guidance
www.americanbankingnews.com - July 27 at 9:59 AM |
| Zimmer Biomet Holdings, Inc. (ZBH) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 24 at 11:32 PM |
| Jana Partners Cleans Up, Exits Whole Foods Stake
finance.yahoo.com - July 21 at 9:00 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:44 AM |
| Cramer explains why CEO departures are not always bad for...
finance.yahoo.com - July 18 at 4:30 AM |
| Zimmer Biomet: Cramer's Top Takeaways
finance.yahoo.com - July 17 at 11:27 PM |
| Cramer explains why CEO departures are not always bad for companies
finance.yahoo.com - July 17 at 6:25 PM |
| Morgan Stanley Increases Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Price Target to $150.00
www.americanbankingnews.com - July 17 at 5:58 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given "Hold" Rating at Stifel Nicolaus
www.americanbankingnews.com - July 15 at 10:34 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - July 15 at 9:44 AM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 12:40 PM |
| Zimmer Biomet Holdings, Inc. (ZBH) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - July 14 at 12:32 PM |
| Zimmer Biomet Holdings' (ZBH) "Buy" Rating Reaffirmed at Bank of America Corporation
www.americanbankingnews.com - July 14 at 12:03 PM |
| Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Earns Market Weight Rating from Wells Fargo & Company
www.americanbankingnews.com - July 14 at 10:44 AM |
| Royal Bank Of Canada Reaffirms "Outperform" Rating for Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
www.americanbankingnews.com - July 14 at 10:18 AM |
Zimmer Biomet Holdings (ZBH) Chart for Thursday, August, 17, 2017
